ARIBIO-CO-LTD
18.6.2020 02:02:05 CEST | Business Wire | Press release
AriBio, a clinical-stage biopharmaceutical company based in South Korea, announced today, June 17th 2020, the completion of enrollment in a Phase 2 study of AR1001, a first in class, orally dosed investigational drug for mild to moderate Alzheimer’s disease. A total of 210 patients are enrolled in the study, and the company is expecting to announce the topline results by early 2021.
“The completion of enrollment is a significant milestone for AriBio, and the company is extremely thankful for the combined efforts of our researchers, partners and the patient community. Advancing safe, effective and meaningful therapies for this devastating disease is our top priority at AriBio, and we look forward to presenting this data in the future,” said James Rock, Senior Vice President of Clinical Operations.
“Patients participating in the study are showing extremely low drop-out rates despite the COVID-19 pandemic and the safety profile of the drug has been encouraging,” said Matthew Choung, Chairman and CEO.
AriBio is the first company from South Korea to fully enroll a Phase 2 study for Alzheimer’s disease in the United States. The company aims to initiate another Phase 2 study for Mixed Dementia in 2021.
About AR1001
AR1001 is a first in class oral therapy with novel polypharmacological mechanisms for the treatment of Alzheimer’s disease. Pre-clinical studies have confirmed neuroprotective effects of AR1001 via inhibiting neuron apoptosis and restoring synaptic plasticity. AR1001 also has demonstrated positive effects against amyloid plaques and tau proteins.
About AR1001-ADP2-US01
AR1001-ADP2-US01 (NCT03625622) is A Double-Blind, Randomized and Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week Treatment of AR1001 in Patients with Mild to Moderate Alzheimer's disease. The study aims to assess the safety and efficacy of AR1001 in slowing the progression of Alzheimer's disease through various cognitive and functional assessments. Last patient visit is expected to occur by the end of 2020. The details of the clinical trial are available at ClinicalTrials.gov.
About AriBio Co., Ltd.
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with a focus on neurodegenerative and infectious diseases. AR1003 is the lead candidate for sepsis and COVID-19, which is preparing to enter a Phase 1 study in the United States by early 2021.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200617005630/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CSG Announces Contract Renewal with DISH Network28.1.2026 14:30:00 CET | Press release
Drives seamless customer experiences and operational agility through 2030. CSG® (NASDAQ: CSGS) today announced a multi-year contract extension with DISH Network to continue powering best-in-class customer service. For 45 years, DISH has been connecting communities across the nation, evolving from a satellite pioneer into a diverse connectivity leader. CSG has been a trusted business enabler for much of that journey and will continue to help DISH support its customers through 2030. “CSG has been instrumental to how DISH serves customers,” said John Swieringa, President, Technology, and Chief Operating Officer, DISH. “Our collaboration with CSG will continue to bring us the flexibility and speed we need to deliver the exceptional experiences our customers deserve.” For three decades, DISH has trusted CSG to manage billing and payment services for millions of subscribers with accuracy and reliability. With CSG’s leading SaaS platform for billing, customer care, and business optimization,
SLB Awarded Multi-Year Contracts to Support Oman’s Energy Development28.1.2026 14:26:00 CET | Press release
Advanced technologies and solutions will help drive production efficiency and maximize recovery SLB (NYSE: SLB) has been awarded two five-year contracts by Petroleum Development Oman (PDO) to supply wellheads and artificial lift technologies for operations in Block-6, Oman’s largest oil and gas concession, while advancing in-country value (ICV). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128443014/en/ The contracts include the provision of low-pressure, high-pressure, and thermal wellheads, as well as electric submersible pumps (ESPs) and progressive cavity pumps (PCPs). These solutions are expected to increase recovery rates and extend the productive life of Block-6 assets. The contracts include the provision of low-pressure, high-pressure, and thermal wellheads, as well as electric submersible pumps (ESPs) and progressive cavity pumps (PCPs). These solutions are expected to increase recovery rates and extend the pro
Canoga Perkins Brings Breakthrough Private 5G Technology to the BLOQUE Innovation Hub in Queretaro, Mexico28.1.2026 14:00:00 CET | Press release
Canoga Perkins, a global leader in Private 5G network connectivity solutions, announces their first international Private 5G Customer Experience Center at the BLOQUE in Queretaro, Mexico. On January 16th, 2026 the company demonstrated the SyncMetra® 100 product and an end-to-end Private 5G solution at the “Experiencing SyncMetra®” event attended by government representatives, city representatives, industry leaders, technology partners, system integrators, resellers and end customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260128847071/en/ Querétaro invests in becoming a global hub for advanced manufacturing, industrial automation, smart agriculture and tech advanced ports applications; the demand for reliable, high-speed connectivity has never been higher. SyncMetra® 100 and Canoga Perkins arrive as critical enablers of Deterministic Networking for all these applications. The SyncMetra Platform offers a software-defi
Motive Once Again Recognized for IoT Leadership28.1.2026 14:00:00 CET | Press release
Wins Gold 2026 Telco Innovation Awards with Deployment at TPG Telecom in Australia Motive, a global leader in mobile device and service management software, has today announced its IMPACT IoT solution has been named the Gold winner for Best Cellular IoT Initiative in the 2026 Telco Innovation Awards. Motive’s IMPACT IoT solution beat off strong competition in the Network & Connectivity Innovation category, which “honours the pioneers building smarter, faster, and more resilient networks for a connected world” to be named as the Best Cellular IoT Initiative. IMPACT IoT offers an intelligent, code-free, cloud-native, and secure network-triggered solution that removes unnecessary signaling and SMS overhead, optimizing eSIM and firmware management for long-lived, low-power devices. The platform is already delivering measurable results for operators like TPG Telecom in Australia, which has deployed IMPACT IoT to power the country's largest smart water meter rollout, serving upwards of 1.7 m
Veracode Releases Platform Enhancements as Software Supply Chain Attacks Surge28.1.2026 13:50:00 CET | Press release
New Preventive Controls and Developer Integrations Powered 2025 Innovation Veracode, the global leader in application risk management, today announced significant platform innovations introduced through the second half of 2025. Headlining the release is Package Firewall, an industry-leading preventive control for software supply chains, advancing the company’s mission to help organizations run secure software from code to cloud. With supply chain-related third-party breaches doubling year over year— from 15 to 30 percent according to the Verizon 2025 Data Breach Investigations Report— the need to strengthen security across the software ecosystem has never been greater. “The growing attack surface has created an unprecedented level of complexity for security and development teams,” said Tim Jarrett, Vice President of Product at Veracode. “The latest enhancements to our platform empower organizations to stop third-party risk from ever entering their software code, providing them with a p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom